Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: J Med Virol. 2017 May 23;89(9):1620–1628. doi: 10.1002/jmv.24809

Figure 2. Sensitivity of both G1 and G3 HCV to SB 9200 compares favourably to Alisporivir.

Figure 2

Sensitivity of patient-derived G1 (A) or G3 (B) HCV to Alisporivir was assessed in the capture-fusion assay and a dose response calculated. Values are mean ± s.e.m. The individual IC50 for SB 9200 and Alisporivir are plotted for G1 (C) and G3 (D).